Subject‐driven titration of biphasic insulin aspart 30 twice daily is non‐inferior to investigator‐driven titration in Chinese patients with type 2 diabetes inadequately controlled with premixed human insulin: A randomized, open‐label, parallel‐group, multicenter trial

Journal of Diabetes Investigation

Wenying Yang²  Lvyun Zhu¹  Bangzhu Meng⁸  Yu Liu¹⁰  Wenhui Wang⁵  Shandong Ye⁶  Li Sun¹³  Heng Miao¹⁴  Lian Guo¹¹  Zhanjian Wang^2,3  Xiaofeng Lv^2,9  Quanmin Li^2,4  Qiuhe Ji^2,7  Weigang Zhao^2,12 

[1] Bethune International Peace Hospital, Shijiazhuang, China;China-Japan Friendship Hospital, Beijing, China;The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, China;The Second Artillery General Hospital of Chinese PLA, Beijing, China;Jinan Central Hospital Affiliated to Shandong University, Jinan, China;Anhui Provincial Hospital, Hefei, China;Xijing Hospital Affiliated to 4th Military Medical University, Xi'an, China;Affiliated Hospital of Inner Mongolia University for the Nationalities, Tongliao, China;The Military General Hospital of Beijing PLA, Beijing, China;The Second Hospital of Jilin University, Changchun, China;Chongqing Three Gorges Central Hospital, Chongqing, China;Peking Union Medical College Hospital, Beijing, China;Siping Central People's Hospital, Siping, China;The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China

关键词: Biphasic insulin aspart;    Titration;    Type 2 diabetes;   

DOI  :  10.1111/jdi.12364

来源: Wiley

【 摘 要 】

Abstract

Aims/Introduction

The present study was to compare the efficacy and safety of subject-driven and investigator-driven titration of biphasic insulin aspart 30 (BIAsp 30) twice daily (BID).

Materials and Methods

In this 20-week, randomized, open-label, two-group parallel, multicenter trial, Chinese patients with type 2 diabetes inadequately controlled by premixed/self-mixed human insulin were randomized 1:1 to subject-driven or investigator-driven titration of BIAsp 30 BID, in combination with metformin and/or α-glucosidase inhibitors. Dose adjustment was decided by patients in the subject-driven group after training, and by investigators in the investigator-driven group.

Results

Eligible adults (n = 344) were randomized in the study. The estimated glycated hemoglobin (HbA_1c) reduction was 14.5 mmol/mol (1.33%) in the subject-driven group and 14.3 mmol/mol (1.31%) in the investigator-driven group. Non-inferiority of subject-titration vs investigator-titration in reducing HbA_1c was confirmed, with estimated treatment difference −0.26 mmol/mol (95% confidence interval −2.05, 1.53) (–0.02%, 95% confidence interval –0.19, 0.14). Fasting plasma glucose, postprandial glucose increment and self-measured plasma glucose were improved in both groups without statistically significant differences. One severe hypoglycemic event was experienced by one subject in each group. A similar rate of nocturnal hypoglycemia (events/patient-year) was reported in the subject-driven (1.10) and investigator-driven (1.32) groups. There were 64.5 and 58.1% patients achieving HbA_1c <53.0 mmol/mol (7.0%), and 51.2 and 45.9% patients achieving the HbA_1c target without confirmed hypoglycemia throughout the trial in the subject-driven and investigator-driven groups, respectively.

Conclusions

Subject-titration of BIAsp 30 BID was as efficacious and well-tolerated as investigator-titration. The present study supported patients to self-titrate BIAsp 30 BID under physicians’ supervision.

【 授权许可】

CC BY-NC-ND   
© 2015 The Authors. Journal of Diabetes Investigation published by Asian Association of the Study of Diabetes (AASD) and Wiley Publishing Asia Pty Ltd

Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.